What Purdue Pharma’s Dissolution Means for Personal Injury Law | Richard Hollawell & Associates
Swedesboro, United States – July 18, 2026 / Richard Hollawell & Associates /
Purdue Pharma is now gone. On May 1, 2026, the company ceased operations as its bankruptcy became effective and its assets moved to Knoa Pharma, a successor structured around public-health goals rather than the older Purdue business model. The change is part of a $7.4 billion settlement tied to Purdue’s role in the opioid crisis, with funds directed to treatment, prevention, recovery, and compensation. The Sacklers are barred from selling opioids in the United States as the new company is subject to tight restrictions, and independent oversight remains in place.
Anyone who does product liability, wrongful death and catastrophic injury knows the broader significance. The Purdue story is not merely the story of one company’s fall. It is about what civil accountability can do when regulators move too slowly, criminal penalties come too late and private misconduct has already done enormous public damage. This point has been made directly in the legal scholarship on opioid and tobacco cases: tort litigation can complement regulation and, in some cases, serve as a catalyst for broader reform by exposing hidden facts, focusing public attention, and forcing change.
What happened before shapes what came next. Back in 2007, someone tied to Purdue – alongside three company leaders – admitted guilt over selling OxyContin under false claims; authorities pointed out they’d wrongly pitched it as harder to get addicted to compared to similar pain drugs. Jump forward to 2020, and Purdue Pharma itself entered another guilty plea, now for three serious crimes: lying to the DEA about tracking pills, pushing opioids to doctors who likely weren’t using them properly, while also handing out forbidden payments to boost prescriptions. Then, in 2024, the U.S. Supreme Court rejected Purdue’s first bankruptcy plan because it would have shielded members of the Sackler family from opioid-related civil lawsuits without the consent of those bringing the claims. Rather than producing a quick resolution, Purdue’s bankruptcy became a long and difficult legal fight over accountability, compensation, and the limits of corporate bankruptcy protections.
Attorney Richard Hollawell puts the lesson plainly:
“Purdue Pharma is responsible for hundreds of thousands of deaths from its false marketing of Oxycontin. Although, Purdue Pharma is no longer in business recently dissolving, the company should have been put out of business in 2007 when executives pled guilty to misbranding charges. Instead of any jail time, the company just paid a small fine as the cost of doing business and it continued its false marketing of Oxycontin. Hopefully, the example of Purdue Pharma will be a lesson for regulators in the future to hold executives criminally accountable for fraudulent behavior that harms the public.”
That perspective captures something important about personal injury law at its best. It is not only a system for awarding damages after harm has already happened. In the right case, it is also a system for forcing truth into the open and for imposing consequences that change how dangerous products are sold. In Purdue’s case, the new successor company cannot market its opioid products, cannot lobby on their behalf, is monitored independently, and is supposed to use excess revenue for opioid abatement. Reuters has also reported that Knoa plans to provide overdose-reversal and addiction-treatment medicines at or below cost. Those are not cosmetic changes. They are structural changes aimed at preventing future harm.
There is also a transparency benefit that should not be overlooked. Connecticut says the settlement requires the release of more than 30 million Purdue and Sackler documents related to the opioid business. That matters because public-health reform is often impossible when the relevant facts stay buried inside a defendant’s files. One of the most important functions of civil litigation is discovery: it creates a record, reveals what companies knew, and allows the public, courts, and policymakers to see patterns of misconduct that would otherwise remain hidden.
Money meant for healing plays a role just like penalties do. According to Reuters, state and city budgets hit by opioid crises will receive much of what Purdue pays out, yet around 865 million dollars heads straight to individuals harmed. Looking beyond one case, plans tied to these legal deals spell out where funds should flow – like handing out naloxone kits, supporting therapy using medicine, offering both home-based and live-in health services, shelters aiding long-term sobriety, hospital ERs guiding patients into rehab, lessons teaching avoidance, plus check-ins with those vulnerable. These paths forward reflect how lawsuits, when aimed right, quietly strengthen community well-being. What matters isn’t just counting up what went wrong. Stopping it from repeating is the real aim.
The need for that kind of repair remains urgent. CDC says approximately 806,000 people died from opioid overdoses from 1999 through 2023. Naloxone can reverse opioid overdose when given in time. Medications for opioid use disorder substantially reduce overdose-related and overall mortality. Yet CDC reported that in 2022 only 25.1% of adults who needed treatment for opioid use disorder received medications for it. Against that backdrop, a settlement structure that pushes money into treatment and prevention and a successor company that promises at-cost access to overdose-reversal and addiction-treatment drugs is more than a legal footnote. It is a concrete example of how civil law can create public-health benefits.
None of this means the system worked perfectly. It did not. Reuters found that more than 40% of individual claims had already been rejected and that many claimants could not produce records showing Purdue manufactured the specific pills involved. That reality is painful, and it is part of the story. Personal injury law can produce accountability, but it often does so only after years of litigation, layers of documentation, and intense procedural fights. That is exactly why experienced plaintiff-side counsel matters. In complex mass-harm cases, the people who were hurt need advocates who understand proof, causation, records, and long-term strategy.
The most important lesson from Purdue, then, is not simply that one notorious company has disappeared. It is that civil law can still do real public work. It can expose misconduct, create a path to compensation, force disclosure, change corporate behavior, and move resources toward treatment and prevention. When personal injury law does all of that, it serves not only the person who was harmed, but the wider public too.
Contact Information:
Richard Hollawell & Associates
121 Saratoga Ln
Swedesboro, NJ 08085
United States
Richard Hollawell
+1-800-681-3550
https://www.richardhollawell.com
